These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25031973)

  • 41. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
    Koprivnikar JL; Cheson BD
    Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
    Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures.
    Korani M; Korani S; Zendehdel E; Nikpoor AR; Jaafari MR; Orafai HM; Johnston TP; Sahebkar A
    Curr Pharm Des; 2019; 25(46):4883-4892. PubMed ID: 31692424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
    Shen L; Au WY; Wong KY; Shimizu N; Tsuchiyama J; Kwong YL; Liang RH; Srivastava G
    Mol Cancer Ther; 2008 Dec; 7(12):3807-15. PubMed ID: 19074855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
    Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
    Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
    Hamuro L; Kijanka G; Kinderman F; Kropshofer H; Bu DX; Zepeda M; Jawa V
    J Pharm Sci; 2017 Oct; 106(10):2946-2954. PubMed ID: 28576695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
    Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
    Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
    Salar A; Avivi I; Bittner B; Bouabdallah R; Brewster M; Catalani O; Follows G; Haynes A; Hourcade-Potelleret F; Janikova A; Larouche JF; McIntyre C; Pedersen M; Pereira J; Sayyed P; Shpilberg O; Tumyan G
    J Clin Oncol; 2014 Jun; 32(17):1782-91. PubMed ID: 24821885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
    Lee HJ; Romaguera JE; Feng L; Desai AP; Zhang L; Fanale M; Samaniego F; Hagemeister FB; Fayad LE; Rodriguez MA; Medeiros JL; Hartig K; Nomie K; Ahmed M; Badillo M; Ye H; Oki Y; Lin P; Nastoupil L; Westin J; Wang M
    Oncologist; 2017 May; 22(5):549-553. PubMed ID: 28408615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteasome inhibitor therapy in multiple myeloma.
    Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
    Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
    Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
    Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
    [No Abstract]   [Full Text] [Related]  

  • 53. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
    Shahshahan MA; Beckley MN; Jazirehi AR
    Am J Cancer Res; 2011; 1(7):913-24. PubMed ID: 22016836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study.
    Roubaud Baudron C; Legeron R; Ollivier J; Bonnet F; Greib C; Guerville F; Cazanave C; Kobeh D; Cressot V; Moneger N; Videau MN; Thiel E; Foucaud C; Lafargue A; de Thezy A; Durrieu J; Bourdel Marchasson I; Pinganaud G; Breilh D
    J Antimicrob Chemother; 2019 Dec; 74(12):3546-3554. PubMed ID: 31730164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
    Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
    Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses.
    Hurley DM; Clarke IJ; Shelton R; Burger HG
    J Clin Endocrinol Metab; 1987 Jul; 65(1):46-52. PubMed ID: 3108305
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
    Robak P; Robak T
    Drugs R D; 2019 Jun; 19(2):73-92. PubMed ID: 30993606
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
    Furtado M; Johnson R; Kruger A; Turner D; Rule S
    Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
    Tobinai K
    Int J Clin Oncol; 2007 Oct; 12(5):318-26. PubMed ID: 17929113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China.
    Yao R; Hu X; Zhou S; Zhang Q; Huang H; Sun N; Guo W; Yu K; Lin Y
    Medicine (Baltimore); 2019 Sep; 98(39):e17147. PubMed ID: 31574817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.